[The experience of application of target sequencing in molecular diagnostic of mucoviscidosis.]

Autor: Simakova TS; 'Parseq lab', 199034, St. Petersburg, Russia., Bragin AG; 'Parseq lab', 199034, St. Petersburg, Russia., Glushkova MA; 'Parseq lab', 199034, St. Petersburg, Russia., Petrova NV; The medical genetic research center, 115478, Moscow, Russia., Polyakov AV; The medical genetic research center, 115478, Moscow, Russia., Kondratieva EI; The medical genetic research center, 115478, Moscow, Russia., Sherman VD; The medical genetic research center, 115478, Moscow, Russia., Pavlov AE; 'Parseq lab', 199034, St. Petersburg, Russia.
Jazyk: ruština
Zdroj: Klinicheskaia laboratornaia diagnostika [Klin Lab Diagn] 2017; Vol. 62 (5), pp. 305-309.
DOI: 10.18821/0869-2084-2017-62-5-305-309
Abstrakt: The mucoviscidosis is one of frequent monogenic diseases. In Russia, in case of mucoviscidosis carrying out of DNA-diagnostic is optional. However, its application permits shortening time of diagnosing, increasing efficiency of of therapeutic treatment and preventing secondary manifestation of disease in family. The DNA-diagnostic using panels on frequent mutations in gene CFTR is recommended in cases of uncertain clinical picture and under borderline values of specific laboratory indices. In Russia, application of such panels permit detecting up to 90% of pathological alleles in gene CFTR. To detect more rare alleles the Sanger sequencing is traditionally applied. Lately, highly productive sequencing techniques became available to detect rare mutations. The actual article presents evaluation of efficiency of application of test-system based on technology of target sequencing for detecting mutations unidentified at primary DNA-diagnostic. Besides, in two patients with mucoviscidosis the application of highly productive sequencing techniques permitted to identify previously unknown nonsense mutations Q1038X (c.3112C>T) и W1310X (c.3930G>A).
Competing Interests: The authors declare no conflict of interest.
Databáze: MEDLINE